Cellyan Biotechnology is seeking Shareholder approval for a share consolidation intended to help keep its Nasdaq listing, with the company addressing a closing price above $1.00 per share. Investors face uncertainty because the company says the action may not sustain the Market Price or ensure continued compliance.

Key Highlights

  • The extraordinary general meeting notice names September 21, 2026, while its heading refers to September 20, 2026.
  • The proposal covers issued and unissued Class A and Class B ordinary shares.
  • The proposed share consolidation would combine every 20 shares of each class into one share.

Cellyan Biotechnology Co. Ltd (NASDAQ: HKPD) is seeking shareholder approval for a share consolidation that it believes could help maintain its Nasdaq listing if the Class A ordinary share closing price exceeds $1.00 per share. The company also cautions that the action may not preserve the market price or satisfy every continued-listing requirement.

Share Consolidation Covers Both Ordinary Share Classes

Each class currently has a nominal or Par Value of $0.001, while the consolidated shares would carry a nominal or par value of $0.02. The company states that the transaction is not intended to constitute a going-private transaction under Rule 13e-3 of the Exchange Act. The extraordinary general meeting notice identifies September 21, 2026, as the meeting date, while the notice heading refers to September 20, 2026.

Company Warns of Market-Value and Listing Risks

Some investors may view the consolidation negatively, according to the company. Even if the closing price exceeds $1.00 per share, Cellyan Biotechnology says it may still be unable to satisfy other Nasdaq continued-listing criteria.